Advertisement

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Advertisement

Advertisement




Dec
07
Today In Oncology
Study Identifies Rectal Bleeding as Key Predictor of Early-Onset Colorectal Cancer
Nivolumab and Ipilimumab in Advanced dMMR/MSI-H Noncolorectal Cancers
T-DXd Plus Pertuzumab in HER2-Positive Advanced or Metastatic Breast Cancer
AACR Pediatric Cancer Progress Report 2025
Camrelizumab Plus Rivoceranib vs Sorafenib for the First-Line Treatment of Unresectable Hepatocellular Carcinoma
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo